We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+46.65%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1B
AUM Growth
+$220M
Cap. Flow
-$11.4M
Cap. Flow %
-1.13%
Top 10 Hldgs %
62.05%
Holding
51
New
6
Increased
3
Reduced
11
Closed
2

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$30.3M
2
CBAY
Cymabay Therapeutics
CBAY
+$12.2M
3
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$11.2M
4
QURE icon
uniQure
QURE
+$8.06M
5
MTNB icon
Matinas BioPharma
MTNB
+$7.34M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$56.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10.5M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.2M
4
APLS
Apellis Pharmaceuticals
APLS
+$7.72M
5
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$4.96M

Sector Composition

Rank Sector Weight
1 Healthcare 97.66%
2 Materials 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
26
Aclaris Therapeutics
ACRS
$726M
$9.87M 0.98%
1,647,214
– –
VRNA
27
DELISTED
Verona Pharma
VRNA
$9.7M 0.97%
1,492,951
– –
DERM
28
DELISTED
Dermira, Inc.
DERM
$9.48M 0.95%
+700,000
New +$5.84M
SLNO
29
DELISTED
Soleno Therapeutics
SLNO
$8.98M 0.9%
290,646
– –
KALA icon
30
KALA BIO
KALA
$14.1M
$8.63M 0.86%
418
– –
ORTX
31
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$8.61M 0.86%
48,161
-33,028
-41% -$4.96M
GLMD icon
32
Galmed Pharmaceuticals
GLMD
$5.13M
$7.94M 0.79%
5,396
– –
AUPH icon
33
Aurinia Pharmaceuticals
AUPH
$1.91B
$7.89M 0.79%
1,213,290
– –
APLS
34
DELISTED
Apellis Pharmaceuticals
APLS
$7.48M 0.75%
383,538
-491,035
-56% -$7.72M
MTNB icon
35
Matinas BioPharma
MTNB
$1.88M
$7.43M 0.74%
+136,364
New +$7.34M
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
$5.78M 0.58%
105,000
– –
DTIL icon
37
Precision BioSciences
DTIL
$180M
$5.04M 0.5%
+9,350
New +$4.96M
GNCA
38
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.61M 0.46%
976,401
-46,099
-5% -$228K
SBBP
39
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.55M 0.45%
+914,062
New +$4.5M
SRRA
40
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.17M 0.42%
60,957
– –
AGRX
41
DELISTED
Agile Therapeutics
AGRX
$2.29M 0.23%
757
– –
ZLAB icon
42
Zai Lab
ZLAB
$2.06B
$2.11M 0.21%
71,595
-10,224
-12% -$280K
DBVT
43
DBV Technologies
DBVT
$799M
$2.08M 0.21%
27,000
– –
TRVN
44
DELISTED
Trevena, Inc.
TRVN
$1.93M 0.19%
1,974
-791
-29% -$595K
TMBR
45
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$1.42M 0.14%
1,075
– –
RNAC icon
46
Cartesian Therapeutics
RNAC
$229M
$1.29M 0.13%
18,202
– –
AKTX
47
Akari Therapeutics
AKTX
$13.8M
$1.24M 0.12%
432
– –
VIRX
48
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$121K 0.01%
2,841
-2,744
-49% -$62.2K
SLNOW
49
DELISTED
Soleno Therapeutics, Inc. Series A Warrant
SLNOW
$28K ﹤0.01%
188,772
– –
ARVN icon
50
Arvinas
ARVN
$518M
– –
-209,666
Closed -$2.69M
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Vivo Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Vivo Capital held 51 positions worth $1B, up 28% from $783M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Vivo Capital's Q1 2019 filing shows 6 new, 3 increased, 11 reduced and 2 closed positions. Its largest new stake was Insmed: 1,170,290 shares worth $34M. The largest sale was Biohaven Pharmaceutical Holding Company Ltd., an estimated $56.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Materials.

  • Vivo Capital's largest Q1 2019 buy was Insmed: 1,170,290 shares worth $34M.
  • Vivo Capital added most to Cymabay Therapeutics in Q1 2019, an estimated $12.2M increase.
  • Vivo Capital's biggest Q1 2019 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $56.5M.
  • Vivo Capital fully exited Arvinas in Q1 2019, selling an estimated $2.69M.
  • Vivo Capital's ten largest holdings make up 62% of its $1B portfolio in Q1 2019.
  • Vivo Capital opened 6 new positions and closed 2 in Q1 2019.
  • Vivo Capital's portfolio value rose 28% quarter-over-quarter to $1B.

Based on Vivo Capital's 13F filing for Q1 2019, filed 14 May 2019.